Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04740476 · ClinicalTrials.gov registry record · Phase 2
An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome
A Phase 2 study of Dravet Syndrome, sponsored by Stoke Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 17
- Study locations
NCT04740476 is a Phase 2 study of Dravet Syndrome that is active but no longer recruiting, run by Stoke Therapeutics. The registered enrollment target is 60 participants, below the 105-participant average among 12 other Dravet Syndrome trials with a reported enrollment target (43% lower). The trial reports 17 study locations across 15 states.
The verdict
NCT04740476, a Phase 2 study of Dravet Syndrome, is active but no longer recruiting, sponsored by Stoke Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 17
- Study locations
Study Summary
Stoke Therapeutics is evaluating the long-term safety \& tolerability of repeated doses of zorevunersen (STK-001) in patients with Dravet syndrome who previously participated in studies of zorevunersen. Change in seizure frequency and overall clinical status, and quality of life will be measured as secondary endpoints in this open-label study.
Conditions Studied
Interventions
- DRUG zorevunersen (STK-001)
Study Locations (17)
Florida
- Nicklaus Children's Hospital - Miami
- Florida Hospital for Children - Orlando
Washington
- Seattle Children's Hospital - Seattle
- MultiCare Health System Institute for Research and Innovation - Tacoma
California
- University of California San Francisco Medical Center - San Francisco
Colorado
- Children's Hospital Colorado - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Iowa
- University of Iowa Children's Hospital - Iowa City
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-01-20 |
| Est. Completion | 2029-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04740476
The ClinicalTrials.gov registry entry for NCT04740476 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 105-participant average among 12 other Dravet Syndrome trials with a reported enrollment target (43% lower). The listed sponsor is Stoke Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dravet Syndrome appearing as the primary indexed condition, and to 1 intervention - of which zorevunersen (STK-001) is the first listed.
NCT04740476 reports 17 study locations spanning 15 distinct geographic areas - top geographies include Florida, Washington, California.
Frequently Asked Questions
What is clinical trial NCT04740476 about?
NCT04740476 is a clinical study titled "An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome". Stoke Therapeutics is evaluating the long-term safety \& tolerability of repeated doses of zorevunersen (STK-001) in patients with Dravet syndrome who previously participated in studies of zorevunersen. Change in seizure frequency and overall clinical status, and quality of life will be measured as ...
What is the current status of trial NCT04740476?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2021-01-20. Estimated completion is 2029-03-31.
What conditions does trial NCT04740476 study?
This clinical trial studies the following conditions: Dravet Syndrome.
What interventions are being tested in trial NCT04740476?
The interventions under investigation include: zorevunersen (STK-001) (DRUG).
Who is sponsoring clinical trial NCT04740476?
This trial is sponsored by Stoke Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04740476 being conducted?
This trial has 17 study locations across California, Colorado, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dravet Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Verapamil as Therapy for Children and Young Adults With Dravet Syndrome
COMPLETED · Phase 2
-
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
COMPLETED · Phase 2
-
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
RECRUITING · Phase 3
-
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
RECRUITING · Phase 1
-
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
RECRUITING · Phase 3
-
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.